CSIMarket
 
Intelgenx Technologies Corp   (IGXT)
Other Ticker:  
 
 
Price: $0.1700 $0.00 2.843%
Day's High: $0.1713 Week Perf: 2.84 %
Day's Low: $ 0.15 30 Day Perf: 21.34 %
Volume (M): 470 52 Wk High: $ 0.26
Volume (M$): $ 80 52 Wk Avg: $0.16
Open: $0.16 52 Wk Low: $0.09



 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 276
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Intelgenx Technologies Corp
Intelgenx Technologies Corp is a pharmaceutical company that focuses on the development and manufacturing of innovative drug delivery technologies. They specialize in oral film drug delivery systems, which are dissolvable strips that deliver medication through the mouth. These films offer advantages such as improved bioavailability, faster onset of action, and ease of use. Intelgenx partners with pharmaceutical companies to license and develop new products using their drug delivery technologies. They also have their own pipeline of generic and branded drugs in development. Overall, Intelgenx Technologies Corp aims to improve the effectiveness and convenience of drug delivery methods.


   Company Address: 6420 Abrams Ville Saint Laurent 0 QC
   Company Phone Number: 331-7440   Stock Exchange / Ticker: IGXT
   IGXT is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Revenue were $0 million at the Neurogene Inc in financial time-frame closing December 31 2023

For the financial time-frame closing December 31 2023 NGNE reached zero gain of $0.00 per share compare to $-6.06 a year ago and from $-0.41 per share from the previous financial reporting period. The revenue remained unchanged to $0.00 million from $0.00 million in the similar financial reporting period a year ago and sequentially from $0.00 million.

Eyenovia Inc

The Major Pharmaceutical Preparations company released Revenue of $0.002589 million, in thefourth quarter of 2023 financial report

EYEN proclaimed $0.002589 million, in Revenue in the October to December 31 2023 fiscal time-frame.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Following the leaders in the Major Pharmaceutical Preparations industry, some lesser known companies are publishing the numbers. ATXI told it has clinched operating loss of $-2.12 million, for the fourth quarter of 2023.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 

Intelgenx Technologies's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com